SCHEMBL4928439

SCHEMBL4928439

CCOc1ccc(-n2c(=O)[nH]c3cc(Cl)c(Cl)cc32)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.50
KMT2A Q03164 5/20 0.50
LMNA P02545 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
TSHR P16473 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
NFKB1 P19838 1/20 0.50
BLM P54132 1/20 0.50
PMP22 Q01453 1/20 0.50
ALDH1A1 P00352 6/20 0.46
HTT P42858 1/20 0.46
MAPT P10636 5/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
HRH3 Q9Y5N1 1/20 0.43
MAPK1 P28482 1/20 0.42
GRIA1 P42261 1/20 0.42
GRIA2 P42262 1/20 0.42
GRIA3 P42263 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4931144 0.90 LMNA (0.48) MEN1KMT2ALMNASMN1; SMN2TSHR
SCHEMBL4930855 0.90 HRH3 (0.49) MEN1KMT2ALMNASMN1; SMN2TSHR
SCHEMBL4933166 0.86 MEN1 (0.49) MEN1KMT2ALMNASMN1; SMN2TSHR
SCHEMBL4929992 0.86 KMT2A (0.63) MEN1KMT2ALMNASMN1; SMN2TSHR
SCHEMBL4934267 0.85 ATM (0.54) MEN1KMT2ALMNASMN1; SMN2TSHR
SCHEMBL4929661 0.84 HRH3 (0.43) MEN1KMT2ALMNASMN1; SMN2TSHR
SCHEMBL4922308 0.79 L3MBTL1 (0.48) MEN1KMT2ALMNASMN1; SMN2TSHR
SCHEMBL8886041 0.79 ATM (0.50) MEN1KMT2ASMN1; SMN2TSHRALDH1A1
SCHEMBL14463860 0.79 HRH3 (0.46) MEN1KMT2ALMNASMN1; SMN2TSHR
SCHEMBL8884813 0.79 MAOB (0.61) MEN1KMT2ATSHRALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
EP-1810677-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2007-07-25 EP disclosed
EP-1810677-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2007-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021069-A1 Receptor Function Regulating Agent GPR119, INSR, GPR65 MEN1 4097/4885KMT2A 1963/4885LMNA 4744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.